Pharmacokinetics of AZD7295 Capsules

A Randomised, Double-Blind, Placebo-Controlled Study to Determine the Pharmacokinetics, Safety and Tolerability of AZD7295 Capsules in Healthy Volunteers

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01097408

Enrollment

Registered

2010-04-01

Start date

2010-03-31

Completion date

2010-08-31

Last updated

2010-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

This is a pharmacokinetics (PK) and safety study of AZD7295 in healthy volunteers.

Interventions

DRUGAZD7295

Up to 650mg AZD7295 capsules per dose. To be given 2 or 3 times daily for 5 days.

DRUGPlacebo comparator

Placebo capsules

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy male or female volunteers, aged 18-65 years.

Exclusion criteria

* Previous exposure to AZD7295, clinically relevant disease.

Design outcomes

Primary

Measure	Time frame	Description
Pharmacokinetics of AZD7295 capsules	0-72h after each dose	PK parameters of AZD7295 will be measured after single and repeated doses (AUC, Cmax, t1/2)

Secondary

Measure	Time frame	Description
Safety and tolerability of AZD7295 capsules	0-72h after each dose	Safety and tolerability of AZD7295 will be assessed after single and repeated doses (adverse events, ECGs, vital signs, safety laboratory tests)

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026